How is ASX200 Resmed Inc (ASX:RMD) Pacing Up to its 1Q Numbers?

Summary

  • ASX200 member ResMed Inc is set to announce its results for the 1st quarter of FY2021 on 29 October 2020.
  • The US-headquartered medical equipment player is working with various stakeholders to deliver ventilation therapy for the treatment of respiratory complications associated with the COVID-19.
  • The ongoing impact of COVID-19 and its anticipated resurgence may create considerable demand for the ResMed’s ventilator products.
  • Further, with sleep disorders diagnosis rate predicted to go up, ResMed could witness significant growth potential in the market.

ASX 200 healthcare player ResMed Inc (ASX:RMD, NYSE:RMD) is likely to release its Q1 FY2021 financial results on 29 October 2020, according to an ASX announcement dated 8 October. The results will be announced after the trading session ends on the New York Stock Exchange.

Let us delve deep and discuss more about ResMed-

About ResMed

ResMed Inc is engaged in developing innovative solutions for treating and keeping individuals out of the hospital. The Company is empowering people to live healthier and high-quality lives.

ResMed’s digital health tech, along with cloud-connected medical tools, provides care to the individuals with diseases including COPD, and sleep apnea, among others.

Moreover, the broad out-of-hospital software platforms of RMD provides support to the professionals and caregivers who help individuals to stay healthy. By offering better care, the Company enhance the quality of life, decrease the impact of chronic illness, and lower the costs for consumers and healthcare systems. The Company has its operations in over 140 countries.

GOOD READ: Government urged to continue MBS-funded telehealth services: ResMed, Resapp to reap the benefits

ResMed to release its Earnings on 29 October 2020

On 8 October 2020, ResMed disclosed that it would release its financial and operational results for the first quarter of the financial year 2020 on 29 October 2020 after closing of the NYSE.

After the release of the results, the management will host a webcast for the discussion of these results.

Respiratory Care and ResMed

In March 2020, the WHO declared COVID-19 as a pandemic, and since then the Company has observed increased requirement of its ventilator devices as well as masks.

Moreover, the Company is working with health authorities, hospitals, physicians, governments, along with patients across the world to assess their needs, and to deliver the ventilation therapy that is important for the treatment of the respiratory complications associated with the COVID-19.

ResMed is working with the main focus of increasing the accessibility of its ventilators as well as other respiratory support devices for the patients who require them most.

Briefing Business Strategy of ResMed, Continued Impact of COVID-19 may create more demand for ResMed’s ventilator products

ResMed stated that sleep apnea and respiratory care markets are predicted to grow in the future because of several factors. Some of these factors include-

  • Increasing awareness of OSA, COPD, and CSA.
  • Improved understanding of the role of treatment of sleep apnea as well as in the managing neurologic, metabolic, cardiac, and some other related conditions.
  • Improved knowledge of the role of non-invasive ventilation for COPD management.
  • An increase in the use of digital as well as product technology for better patient outcomes and generate efficiencies for customers and providers.
  • Furthermore, the continued effect of COVID-19 or its resurgence may create more demand for the ventilator products of ResMed.

RELATED: Can rising COVID-19 cases push these stocks further north? (RMD, FPH, ANN)

ResMed’s Financial Year 2020 Highlights

Highlights from the financial front-

  • During the financial year 2020, the revenue of RMD rose by 13% to US$3.0 billion; up 15% on constant currency (cc) basis.
  • For Q4 FY2020, revenue was up 9% to US$770.3 million (+10% on cc basis).
  • GAAP gross margin was 58.1%, and non-GAAP gross margin expanded 80 bps to 59.8%.
  • Net operating profit during the period rose by 40% and non-GAAP operating profit increased by 24%.
  • In the fiscal year 2020, ResMed had GAAP diluted earnings per share of US$4.27; non-GAAP diluted earnings per share were US$4.76.

Highlights from the business and operational front-

  • The Company accelerated the cloud-based remote monitoring software launch for ventilators as well as for Lumis devices in Europe, through the AirView platform.
  • During the FY20, ResMed launched ResMed MaskSelector, which is a digital tool for remote patient mask selection, sizing easier and more effective, helping patients in receiving the care from home.

Stock Information

On 9 October 2020, RMD share price stood at A$24.110, down by 0.864%. ResMed has a market capitalisation of approximately A$35.24 billion. The 52-weeks high and low price were noted at A$29.300 and A$18.100, respectively.

Bottomline

The continued demand for ResMed’s ventilators and masks, coupled with the anticipated rise in diagnosis rate of sleep-related disorders, has put ResMed in a good position with expectations of a strong Q1 performance. The impressive financial results and rising demand has boosted investor confidence, evident in the substantial rise in RMD share price in 2020. The resurgence in COVID-19 cases across multiple geographies might create further prospects for the medical equipment company in the coming days.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK